389 related articles for article (PubMed ID: 26110555)
1. Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases.
Deroose JP; Grünhagen DJ; Eggermont AM; Verhoef C
Melanoma Res; 2015 Oct; 25(5):427-31. PubMed ID: 26110555
[TBL] [Abstract][Full Text] [Related]
2. Isolated limb perfusion for in-transit melanoma metastases: melphalan or TNF-melphalan perfusion?
Hoekstra HJ; Veerman K; van Ginkel RJ
J Surg Oncol; 2014 Mar; 109(4):338-47. PubMed ID: 24403098
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
[TBL] [Abstract][Full Text] [Related]
4. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
[TBL] [Abstract][Full Text] [Related]
5. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
[TBL] [Abstract][Full Text] [Related]
6. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study.
Liénard D; Eggermont AM; Koops HS; Kroon B; Towse G; Hiemstra S; Schmitz P; Clarke J; Steinmann G; Rosenkaimer F; Lejeune FJ
Melanoma Res; 1999 Oct; 9(5):491-502. PubMed ID: 10596916
[TBL] [Abstract][Full Text] [Related]
7. Isolated limb perfusion for unresectable melanoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
[TBL] [Abstract][Full Text] [Related]
8. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
[TBL] [Abstract][Full Text] [Related]
9. Response and Toxicity of Repeated Isolated Limb Perfusion (re-ILP) for Patients With In-Transit Metastases of Malignant Melanoma.
Belgrano V; Pettersson J; Nilsson JA; Mattsson J; Katsarelias D; Olofsson Bagge R
Ann Surg Oncol; 2019 Apr; 26(4):1055-1062. PubMed ID: 30617871
[TBL] [Abstract][Full Text] [Related]
10. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas.
Deroose JP; Eggermont AM; van Geel AN; Burger JW; den Bakker MA; de Wilt JH; Verhoef C
J Clin Oncol; 2011 Oct; 29(30):4036-44. PubMed ID: 21931039
[TBL] [Abstract][Full Text] [Related]
11. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients.
Takkenberg RB; Vrouenraets BC; van Geel AN; Nieweg OE; Noorda EM; Eggermont AM; Kroon BB
J Surg Oncol; 2005 Aug; 91(2):107-11. PubMed ID: 16028280
[TBL] [Abstract][Full Text] [Related]
12. Tumour response after hyperthermic isolated limb perfusion for locally advanced melanoma.
Paulsen IF; Chakera AH; Drejøe JB; Klyver H; Dahlstrøm K; Oturai PS; Mortensen J; Hesse B; Schmidt G; Drzewiecki K
Dan Med J; 2014 Jan; 61(1):A4741. PubMed ID: 24393586
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of 163 consecutive patients treated with isolated limb perfusion for in-transit metastases of malignant melanoma.
Olofsson R; Mattsson J; Lindnér P
Int J Hyperthermia; 2013 Sep; 29(6):551-7. PubMed ID: 23865737
[TBL] [Abstract][Full Text] [Related]
14. Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma.
Zogakis TG; Bartlett DL; Libutti SK; Liewehr DJ; Steinberg SM; Fraker DL; Alexander HR
Ann Surg Oncol; 2001 Dec; 8(10):771-8. PubMed ID: 11776490
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of isolated limb perfusion with tumour necrosis factor-α for patients with melanoma in-transit metastases.
Deroose JP; Grünhagen DJ; van Geel AN; de Wilt JH; Eggermont AM; Verhoef C
Br J Surg; 2011 Nov; 98(11):1573-80. PubMed ID: 21739427
[TBL] [Abstract][Full Text] [Related]
16. Isolated limb perfusion in primary and recurrent melanoma: indications and results.
Liénard D; Eggermont AM; Kroon BB; Schraffordt Koops H; Lejeune FJ
Semin Surg Oncol; 1998; 14(3):202-9. PubMed ID: 9548602
[TBL] [Abstract][Full Text] [Related]
17. TNF dose reduction in isolated limb perfusion.
Grünhagen DJ; de Wilt JH; van Geel AN; Graveland WJ; Verhoef C; Eggermont AM
Eur J Surg Oncol; 2005 Nov; 31(9):1011-9. PubMed ID: 16099618
[TBL] [Abstract][Full Text] [Related]
18. Isolated limb perfusion prolongs the limb recurrence-free interval after several episodes of excisional surgery for locoregional recurrent melanoma.
Noorda EM; Takkenberg B; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Hart GA; Kroon BB
Ann Surg Oncol; 2004 May; 11(5):491-9. PubMed ID: 15078633
[TBL] [Abstract][Full Text] [Related]
19. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics.
Bartlett DL; Ma G; Alexander HR; Libutti SK; Fraker DL
Cancer; 1997 Dec; 80(11):2084-90. PubMed ID: 9392330
[TBL] [Abstract][Full Text] [Related]
20. Isolated limb perfusion for melanoma in-transit metastases: developments in recent years and the role of tumor necrosis factor alpha.
Deroose JP; Eggermont AM; van Geel AN; Verhoef C
Curr Opin Oncol; 2011 Mar; 23(2):183-8. PubMed ID: 21150602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
